2023-508558-25-01RecruitingPhase 1/2
Tolerogenic dendritic cell therapy in type 1 diabetes; a phase 1b safety and immunological effecitivity study
Source: EU CTIS (euclinicaltrials.eu) · Last updated 24 Mar 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 21 Jun 2024
- Start date
- 2 Dec 2024
- Lead sponsor
- Academisch Ziekenhuis Leiden
- Diseases
- Type 1 diabetes
- EU CT number
- 2023-508558-25-01
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 10
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Academisch Ziekenhuis Leiden | Leiden | Netherlands | Recruiting |
| Diabeter Nederland B.V. | Rotterdam | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.